Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Melanotan II Peptide: Interactions with Melanocortin Receptors

Melanotan II Interactions with Melanocortin Receptors Apr 15, 2025 The cyclic structure of Melanotan II is posited to significantly support its binding affinity to various melanocortin receptors, most notably the melanocortin 1 receptor (MC1R). However, resear

By Recovery & Performance Peptides Editorial Team

Melanotan II Interactions with Melanocortin Receptors

Apr 15, 2025

The cyclic structure of Melanotan II is posited to significantly support its binding affinity to various melanocortin receptors, most notably the melanocortin 1 receptor (MC1R). However, researchers such as Wikberg et al. highlight that the peptide is also not particularly selective and binds to other melanocortin receptors with high affinity, such as the melanocortin 4 receptor (MC4R) subtypes.(1) Melanotan II demonstrates a wider range of potential research implications due to this increased receptor affinity.

Through its interaction with MC1R, Melanotan II may stimulate melanogenesis—the biological process responsible for skin cell pigmentation. Additionally, its binding to MC4R may impact copulatory signaling and metabolic regulation, further broadening its potential physiological impacts. In addition, Melanotan II also appears to interact with the melanocortin 3 and melanocortin 5 receptors, but these interactions are less extensively studied. Below, we will break down the interactions between Melanotan II and different receptors, highlighting the specific research implications that these interactions may allow.

Research

Melanotan II and Melanocortin 1 Receptor Activation

The MC1Rs are receptors that may be expressed in the pigment cells called melanocytes, which are found in tissues such as dermal tissues and hair. Melanotan II appears to bind to MC1R with activity that may be greater than that of other α-MSH analogs, as suggested by research from Dorr et al.(2) This interaction is posited to trigger a cascade of intracellular signaling events mediated by the so-called G protein pathway. Specifically, activation of MC1R may lead to the stimulation of adenylate cyclase, an enzyme that converts adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP).

Elevated cAMP levels subsequently activate protein kinase A (PKA). The latter typically phosphorylates and activates the cAMP response element-binding protein (CREB) transcription factor. Once activated, CREB may translocate to the melanocyte’s nucleus. It is posited to promote the transcription of several genes crucial for melanogenesis, particularly the gene encoding microphthalmia-associated transcription factor (MITF).

MITF is thought to act as a master regulator of melanogenesis, supporting the transcription of multiple enzymes essential to melanin synthesis, notably tyrosinase, tyrosinase-related protein 1 (TRP1), and dopachrome tautomerase (DCT or TRP2). Tyrosinase, in particular, is a critical enzyme that catalyzes the initial step in melanin biosynthesis, converting the amino acid tyrosine into L-DOPA, which is further converted into dopaquinone. This molecule serves as a precursor for eumelanin, the dark brown or black form of melanin responsible for pigmentation and photoprotection in skin tissues.

Melanotan II and Oxidative Stress Management via the MC1R

Research by Wu et al. also suggests that after binding to MC1R, Melanotan II increases the cellular expression of phosphatase and tensin homolog (PTEN), which is considered an essential regulator of a cell’s antioxidant response.(3) PTEN typically counteracts oxidative stress by negatively regulating the PI3K/AKT signaling pathway, a critical cascade involved in cell proliferation, inflammation, and survival. The researchers commented that “MTII dose-dependently increased the phosphatase and tensin homolog (PTEN) protein level while reducing PTEN phosphorylation, which resulted in the inhibition of AKT/nuclear factor kappa B (NFκB) signaling”.

The mechanism by which Melanotan II supports PTEN levels involves a reduction in PTEN phosphorylation, potentially leading to increased stability and activity of the PTEN protein. This may suppress the downstream signaling of AKT and nuclear factor kappa B (NFκB), pathways widely recognized for their roles in inflammatory responses, oxidative stress, and tumor cell progression. NFκB suppression is particularly relevant, given its involvement in inducing cyclooxygenase-2 (COX-2), an enzyme intimately linked to inflammation and oxidative stress through prostaglandin E2 (PGE2) production. Melanotan II experimentation resulted in the concentration-dependent inhibition of COX-2 expression and subsequent reduction in PGE2 production, suggesting a potential anti-inflammatory impact that may indirectly contribute to reduced oxidative stress.

Interestingly, previous research has also posited that α-MSH, through similar MC1R-dependent signaling pathways, may reduce oxidative stress and DNA damage induced by UV radiation in melanocytes. Since Melanotan II is a more stable and potent analogue of α-MSH, it is reasonable to speculate that a similar mechanism may also be activated by Melanotan II, potentially offering protection against UV-induced oxidative damage at the cellular level. However, it is also important to note that some researchers, such as Hjuler et al., suggest Melanotan II may stimulate the proliferative potential of melanocytes and increase the potential risk of melanocyte metaplasia, which is a risk factor for the formation of cancer cells.(4)

Melanotan II and Arousal Regulation via the MC4R

The MC4Rs are another group of melanocortin receptors localized in the central nervous system, most likely in the hypothalamus. These receptors are thought to play a role in regulating two major systems – the systems that regulate hunger hormone signaling and the systems that regulate mating-related signaling and copulatory arousal. Melanotan II appears to bind with the MC4R, consequently impacting multiple neural circuits involving regions such as the medial preoptic area (MPOA), the paraventricular nucleus (PVN), and the arcuate nucleus (Arc) of the hypothalamus. These areas are critical in the initiation and regulation of mating-related signaling. Melanotan II may modulate oxytocinergic signaling, potentially interacting with pathways that directly impact spinal erection centers.

Research by King et al.a also suggests that MC4R mRNA has been identified in various neuronal populations linked to penile erection pathways, implicating spinal sites of action for melanocortin agents such as Melanotan II.(5) The peptide has reportedly led to increases in spontaneous erections in laboratory models, which were potentially mediated via sympathetic innervation, suggesting that melanocortin agonists like Melanotan II possibly modulate sympathetic pathways. Further research by Wessells et al. has suggested that the peptide may induce increased arousal neuron signaling in more than 80% of cases, compared to only 20% success with a placebo.(6)

Melanotan II Impact on Cell Survival via the MC4R

Researchers like Ter Laak et al.. hypothesized that MC4R activation might play a role in neuronal cell recovery, possibly by facilitating neurite outgrowth.(7) Neurite outgrowth refers to the process by which neurons extend axons and dendrites, potentially supporting the intrinsic regenerative capacity of neuronal tissue following injury. While the precise signaling pathways remain incompletely defined, current theories frequently highlight the potential involvement of peptides derived from pro-opiomelanocortin (POMC). POMC-derived peptides.

These peptides are speculated to impact neuronal architecture by possibly increasing both the number and the elongation of neurites—thin projections from neurons essential for neural network formation—and might even encourage nerve sprouting in regions experiencing damage. By binding to MC4R, Melanotan II may result in a better-supported environment for nerve fiber regeneration after diverse neuronal insults, including physical injury or neurotoxic damage. Furthermore, Melanotan II may also induce limited neuroprotective actions, potentially mitigating the detrimental impact of toxic neuropathic conditions in laboratory models. Ter Laak et al.. noted that they “observed that Melanotan-II also possesses neuroprotective properties, as it partially protected the nerve from a toxic neuropathy induced by cisplatin.”

Melanotan II and Hunger Hormone Regulation via MC4R

Research by Côté et al. suggested that Melanotan II possibly impacts hunger hormone signaling through its potential action on MC3 and MC4Rs.(8) The researchers suggest that the peptide may cause a concentration-dependent anorexic response. Specifically, a reduction in caloric intake ranging from approximately 30% to 50% was observed shortly after the experimentation began. However, this hunger hormone signal-suppressing action was transient, returning to baseline levels within 2 to 5 days of continuous exposure. This also indicates possible receptor desensitization or compensatory mechanisms.

Furthermore, another potential mechanism related to Melanotan II may impact energy expenditure pathways, notably thermogenesis and adipose tissue metabolism. The research linked the peptide to a 3-fold increase in uncoupling protein 1 (UCP1) content in interscapular brown adipose tissue (iBAT), indicating potentially better-supported thermogenic capacity. Increased thermogenesis, mediated through the activation of brown adipose tissue, may contribute to fat mass loss and suppressed hunger hormone signaling. The researchers noted an approximate 35% – 55% reduction in fat cell mass. Unfortunately, a reduction in lean mass was also reported, reaching up to 30%.

You can find Melanotan 2 for sale with 99% purity, on our website (available for research use only).

NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

References:

Wikberg JE. Melanocortin receptors: perspectives for novel drugs. Eur J Pharmacol. 1999 Jun 30;375(1-3):295-310. doi: 10.1016/s0014-2999(99)00298-8. PMID: 10443584.

Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-84. doi: 10.1016/0024-3205(96)00160-9. PMID: 8637402.

Wu JC, Tsai HE, Hsiao YH, Wu JS, Wu CS, Tai MH. Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition. Int J Mol Sci. 2020 Jan 20;21(2):681. doi: 10.3390/ijms21020681. PMID: 31968661; PMCID: PMC7013727.

Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014;228(1):34-6. doi: 10.1159/000356389. Epub 2013 Dec 18. PMID: 24355990.

King, Stephen H et al. “Melanocortin receptors, melanotropic peptides and penile erection.” Current topics in medicinal chemistry vol. 7,11 (2007): 1098-1106. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694735/

Wessells, H et al. “Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.” International journal of impotence research vol. 12 Suppl 4 (2000): S74-9. doi: 10.1038/sj.ijir.3900582. https://pubmed.ncbi.nlm.nih.gov/11035391/

Ter Laak MP, Brakkee JH, Adan RA, Hamers FP, Gispen WH. The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. Eur J Pharmacol. 2003 Feb 21;462(1-3):179-83. doi: 10.1016/s0014-2999(02)02945-x. PMID: 12591111.

Côté I, Sakarya Y, Kirichenko N, Morgan D, Carter CS, Tümer N, Scarpace PJ. Activation of the central melanocortin system chronically reduces body mass without long-term caloric restriction. Can J Physiol Pharmacol. 2017 Feb;95(2):206-214. doi: 10.1139/cjpp-2016-0290. Epub 2016 Oct 19. PMID: 28051332; PMCID: PMC5572812.

Dr. Marinov

Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.

Latest Blog Articles

Thymogen Potential in Immune Cell Regulation

CJC-1295 & Hexarelin Blend Potential for Growth Hormone Signaling Stimulation

Oxytocin Actions On Neuronal Circuits in Different Mammalian Research Models

Kisspeptin 45-54 Peptide Interactions with Hypothalamic and Neuronal Cells

T-31 Peptide Interactions with Cellular Aging, Renewal, and Stress Pathways

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosages

Melanotan II dosages vary depending on the intended usage and personal reaction, but there are no established medical standards due to restricted regulatory approval. For skin pigmentation, users commonly begin with subcutaneous injections of 0.25 to 0.5 milligrams daily, continuing for several days until the desired tan develops. Maintenance doses, typically 0.1 to 0.5 milligrams, are often administered once or twice weekly to preserve the effect. For erectile dysfunction, initial doses of 0.25 to 1 milligram are used, adjusted according to effectiveness and tolerance. Doses are generally kept low to reduce side effects such as nausea or flushing.
SIDE EFFECTS

Side Effects

Common Side Effects: Nausea (most frequent, especially with initial doses) Facial flushing and warmth Fatigue or drowsiness Appetite suppression Spontaneous or prolonged erections in men Less Common Side Effects: Darkening of existing moles and freckles Development of new nevi (moles) Injection site reactions (redness, pain, swelling) Headache Dizziness Concerns Requiring Attention: Mole darkening raises melanoma concerns due to MT-II's direct stimulation of melanocytes. Multiple published case reports in peer-reviewed journals, including the British Journal of Dermatology, have documented melanomas arising during MT-II use. Both the UK's MHRA and Australia's TGA have issued formal safety warnings specifically citing melanoma risk. While definitive population-level causality has not been established through large-scale epidemiological studies, the evidence goes well beyond theoretical concern. Those with numerous atypical moles, a personal or family history of melanoma, or very fair skin (Fitzpatrick type I) are at particular risk. Regular dermatological monitoring is advisable for anyone using MT-II. The Wessells 1998 study showed dose-dependent erections lasting 1–5 hours in subjects receiving MT-II, and priapism (erection lasting more than 4 hours) is a recognized risk. Priapism constitutes a urological emergency requiring immediate attention, as delayed treatment can result in permanent erectile dysfunction.
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Researchers Cited in This Article

The researchers below authored or co-authored publications cited in this article. Listing them here identifies sources; it does not mean they wrote, independently reviewed, sponsored, or endorsed this PeptideDosages.com article. The site author is identified in the article byline.

RESEARCH

Melanotan II MC1R Research: Melanogenesis Pathway Studies in Melanocyte Cell Models

Melanotan II MC1R Research: Melanogenesis Pathway Studies in Melanocyte Cell Models Melanotan II represents a synthetic analog of α-melanocyte stimulating hormone (α-MSH) extensively studied in cell-based assay formats for its broad melanocortin receptor (MC1R, MC3R, MC4R, MC5R) binding and cAMP signaling. Published in vitro research characterizes its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions. Receptor Pharmacology and Mechanism of Action Melanotan II demonstrates agonist activity at multiple melanocortin receptor subtypes through direct receptor binding and subsequent G-protein coupled receptor (GPCR) activation. The compound exhibits particularly high binding affinity for MC1R expressed in melanocyte cell lines, with Ki values in the nanomolar range according to radioligand displacement assays. Comparative binding studies reveal differential receptor selectivity profiles across melanocortin receptor subtypes, with MC1R and MC4R showing enhanced binding kinetics relative to MC3R and MC5R in heterologous expression systems. The primary signaling mechanism involves adenylyl cyclase activation following receptor occupancy, resulting in elevated intracellular cyclic adenosine monophosphate (cAMP) concentrations. Fluorescence-based cAMP accumulation assays demonstrate dose-dependent responses in transfected cell models, with EC50 values typically ranging from 0.1-10 nM depending on receptor subtype and cellular expression levels. Melanogenesis Pathway Activation cAMP-PKA Signaling Cascade Following MC1R activation in melanocyte cell models, elevated cAMP levels trigger protein kinase A (PKA) phosphorylation events that propagate melanogenesis signaling. In vitro kinase assays demonstrate PKA-mediated phosphorylation of cAMP response element-binding protein (CREB) at serine-133, facilitating transcriptional activation of melanogenic enzymes. Time-course studies in B16 melanoma cell lines reveal peak CREB phosphorylation occurring 15-30 minutes post-treatment, correlating with downstream gene expression changes. Tyrosinase Expression and Activity Melanotan II treatment in melanocyte cell cultures induces significant upregulation of tyrosinase, the rate-limiting enzyme in melanin biosynthesis. Quantitative PCR analysis demonstrates 3-8 fold increases in tyrosinase mRNA expression within 6-12 hours of receptor activation. Western blot analysis confirms corresponding protein level increases, with peak tyrosinase expression occurring 24-48 hours post-treatment in immortalized melanocyte cell lines. Enzymatic activity assays measuring L-DOPA oxidation reveal enhanced tyrosinase catalytic function following Melanotan II exposure. Spectrophotometric analysis of dopachrome formation demonstrates dose-dependent increases in enzyme activity, with maximal stimulation occurring at concentrations corresponding to receptor saturation in binding studies. Comparative Receptor Binding Studies Melanocortin Receptor Selectivity Competition binding experiments utilizing radiolabeled α-MSH reveal distinct binding profiles for Melanotan II across melanocortin receptor subtypes. Scatchard analysis in CHO cells expressing individual receptor subtypes demonstrates highest affinity binding at MC1R (Ki ~0.2 nM) and MC4R (Ki ~0.5 nM), with reduced affinity at MC3R (Ki ~2.1 nM) and MC5R (Ki ~1.8 nM) under standard assay conditions. Structure-activity relationship studies comparing Melanotan II with endogenous α-MSH reveal enhanced receptor binding stability due to cyclization and D-amino acid substitutions. These modifications confer resistance to peptidase degradation while maintaining receptor activation potency in cell-based functional assays. Downstream Signaling Pathways MITF Transcriptional Regulation MC1R activation triggers microphthalmia-associated transcription factor (MITF) upregulation through PKA-mediated phosphorylation events. Immunofluorescence microscopy in cultured melanocytes demonstrates nuclear MITF accumulation following Melanotan II treatment, with quantitative analysis revealing 4-6 fold increases in nuclear fluorescence intensity. Chromatin immunoprecipitation assays confirm enhanced MITF binding to tyrosinase gene promoter sequences, establishing the transcriptional mechanism underlying melanogenic enzyme induction. Melanin Synthesis Quantification Direct melanin content analysis in Melanotan II-treated cell cultures employs spectrophotometric measurement following sodium hydroxide extraction. Dose-response studies demonstrate concentration-dependent melanin accumulation with saturable kinetics, reaching plateau levels at 10-100 nM depending on cell line characteristics and culture duration. High-performance liquid chromatography analysis distinguishes eumelanin and pheomelanin production ratios, revealing preferential eumelanin synthesis in MC1R-expressing cell models. Research Summary In vitro pharmacological characterization of Melanotan II demonstrates potent melanocortin receptor agonist activity with particular selectivity for MC1R subtypes. The compound effectively activates cAMP-PKA signaling cascades leading to CREB phosphorylation, MITF upregulation, and subsequent tyrosinase expression increases. Quantitative analysis of melanogenesis endpoints confirms robust melanin synthesis stimulation in appropriate cell model systems. These receptor-mediated effects establish Melanotan II as a valuable research tool for investigating melanocortin signaling pathways and melanogenic regulatory mechanisms in controlled laboratory environments. All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition. Hexarelin TB-500 Epithalon Ipamorelin Tirzepatide CJC-1295 DAC PT-141 Semaglutide Selank BPC-157 Sermorelin Melanotan 2 IGF LR3 Tesamorelin AICAR IGF-DES GHRP 2 Albuterol Tamoxifen Letrozole Clomiphene Tadalafil Clenbuterol Anastrozole Finasteride Exemestane Sildenafil Yohimbine Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows Already a customer? Sign In Create Account All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. Sarms Stacks Research Liquids Albuterol 5MG/ML | 30ML with dropper Anastrozole 1.5MG/ML | 30ML with dropper Clomiphene 50MG/ML | 30ML with dropper Finasteride 5MG/ML | 30ML with dropper Letrozole 3.5 MG/ML | 30ML with dropper LiquiCia 30MG/ML | 30ML with dropper LiquiCia T50 50MG/ML | 30ML with dropper LiquiClen 200MCG/ML | 30ML with dropper Liquistane / Exemestane 25MG/ML | 30ML with dropper LiquiTamo 20MG/ML | 30ML with dropper LiquiVia 25MG/ML | 30 ML with dropper T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper Toremifene Citrate 60MG/ML | 30ML with dropper Yohimbine HCL 10MG/ML | 30ML with dropper Research Peptides Aicar 50MG BPC-157 + TB-500 Blend 2mg ea/ 4MG BPC-157 5MG CJC-1295 + DAC 2MG CJC-1295 | No DAC 2MG Epithalon 10MG Frag Premium 176-191 5MG GHK-CU Copper Peptide 50MG GHRP-2 5MG GHRP-6 5MG Hexarelin 5MG IGF-1 DES 1MG IGF-1 LR3 1MG Ipamorelin 5MG Melanotan 2 10MG NAD+ 500MG PT-141 / Bremelanotide 10MG GLP-1/GIP/GCG (RT) Selank 5MG GLP1 (SM) Sermorelin 5MG TB-500 5MG GIP/GLP-1 (TZ) PDE5 Inhibitors GLP-1 Diluents Bacteriostatic Water 10ML

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Study Doses Versus Personal Medical Advice

Published melanotan-II studies used protocol-defined dosing and monitoring, which is different from personal use of unapproved products [2], [7]. Study doses should not be interpr…

Comparison

Melanotan II Versus Related Melanocortin Compounds

Melanotan II is best understood in the context of its relatives, because vendors exploit the confusion among them and because the comparison clarifies what “approved” actually mea…

Comparison

Selective versus Non-Selective: the Afamelanotide and Bremelanotide Comparison

The clearest way to understand Melanotan II’s place in pigmentation research is to see it against the two approved melanocortin drugs that flank it. The comparison is not academic…

Continue reading

Related articles